ZappRx Inc., a digital health company focused on modernizing and expediting the specialty drug prescribing process, closed $25 million in Series B funding led by Qiming U.S. Healthcare Fund, a venture capital firm based in Seattle that is part of a broader family of Qiming Venture Partners.
The Series B round included participation from SR One, who led ZappRx’s Series A round in 2014, and GV (formerly Google Ventures). As part of the financing, Mark McDade, the managing partner at Qiming